Bank Of America Corp Inhibrx, Inc. Transaction History

Bank Of America Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$32.76 - $39.56 $1.59 Million - $1.92 Million	48,611 Added 7.01%	741,591 $25.9 Million
Q4 2023 Feb 14, 2024	BUY	$14.5 - $38.0 $8.56 Million - $22.4 Million	590,137 Added 573.82%	692,980 $26.3 Million
Q2 2023 Aug 14, 2023	SELL	$16.96 - $27.82 $1.42 Million - $2.33 Million	-83,898 Reduced 44.93%	102,843 $2.67 Million
Q1 2023 May 12, 2023	BUY	$18.45 - $27.14 $743,055 - $1.09 Million	40,274 Added 27.5%	186,741 $3.52 Million
Q4 2022 Feb 10, 2023	BUY	$20.18 - $33.33 $374,883 - $619,171	18,577 Added 14.53%	146,467 $3.61 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $1.35 Million - $2.87 Million	116,255 Added 999.18%	127,890 $2.3 Million
Q2 2022 Aug 12, 2022	SELL	$8.52 - $25.26 $398,165 - $1.18 Million	-46,733 Reduced 80.07%	11,635 $132,000
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $238,222 - $517,166	11,977 Added 25.82%	58,368 $1.3 Million
Q4 2021 Feb 08, 2022	BUY	$26.75 - $46.02 $724,630 - $1.25 Million	27,089 Added 140.34%	46,391 $2.03 Million
Q3 2021 Nov 15, 2021	BUY	$25.18 - $37.81 $289,821 - $435,193	11,510 Added 147.72%	19,302 $643,000
Q2 2021 Sep 13, 2021	BUY	$14.69 - $27.52 $114,464 - $214,435	7,792 New	7,792 $214,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $580M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.